ClinicalTrials.gg
CompletedNCT01073605Updated Nov 18, 2010Results posted

Genotropin Treatment in Short Prepubertal Children With Intra-Uterine Growth Retardation

A Phase 3 interventional study of Genotonorm and Genotonorm in Growth Disorders and Intrauterine Growth Retardation, sponsored by Pfizer. Completed at 30 sites in France. Open to participants aged 3 Years to 12 Years. Per ClinicalTrials.gov, last updated 2010-11-18.

Primary conditionFetal Growth RetardationRegistry: Growth DisordersReclassifiedWhy we changed it
Registry
Growth Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Fetal Growth Retardation
Why
  1. The study's listed conditions name Fetal Growth Retardation, a narrower term within Growth Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
3 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Fetal Growth Retardation with a site in France — 8 open to participants now, 8 under way, 2 of them phase 3. Fetal Growth Retardation · France.

Enrollment
8th of 16
208 · median 207
Started
1993
with 1 other
Phase 3
7 of 29
2 open now
Registered
6th of 29
by date
Lead sponsor
2 of 29
Pfizer

Among the 29 studies in Fetal Growth Retardation with a site in France, this one is the 8th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 1993, is one of 7 in phase 3, and was the 6th registered.

Fetal Growth Retardation

262 studies on the registry are indexed under Fetal Growth Retardation; 69 are open to participants now.

Browse Fetal Growth Retardation studies →

Open to participants now

8 of the 29 studies in Fetal Growth Retardation with a site in France are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 48 Fetal Growth Retardation studies recruiting now, 24 (50%) set no upper age limit and 21 (44%) stop at 75 or younger; 16 take children under 18; 24 take healthy volunteers.

This study: 3 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Fetal Growth Retardation with a site in France, or all of them as a file.
02

Study summary

To evaluate the effect of continuous and intermittent administration of Genotonorm on stature in short prepubertal children with intra-uterine growth retardation

03

Conditions studied

  • Growth Disorders
  • Intrauterine Growth Retardation

Browse trials for

Keywords

  • Short height
  • intra-uterine growth retardation
  • Genotonorm
  • continuous treatment
  • intermittent treatment
04

In context

Fetal Growth Retardation Reclassified

262 studies on the registry are indexed under Fetal Growth Retardation; 69 are open to participants now.

This study's enrollment of 208 is above the median of 150 across 110 interventional studies indexed under Fetal Growth Retardation.

Browse Fetal Growth Retardation studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Compared within Fetal Growth Retardation, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Growth Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
3 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronological age (CA) between 3 and 10 for girls
  • Chronological age between 3 and 12 for boys
  • Height for CA below - 2 SD
  • Birth length for CA below -2SD

Exclusion criteria

Exclusion Criteria:

  • Endocrine disease except well-substituted hypothyroidism
  • Sever chronic disease
  • Skeletal dysplasia
  • Known chromosomal aberration
  • Ongoing treatment with
  • Known intrauterine infection
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
208 participants (actual)

Study arms

  • Active comparator
    Genotonorm A

    Continuous 0.7 IU/kg/week or 0.03 mg/kg/day

    Drug: Genotonorm

  • Active comparator
    Genotonorm B

    Continuous, 1.4 IU/kg/week or 0.06 mg/kg/day

    Drug: Genotonorm

  • Active comparator
    Genotonorm C

    Intermittent, 1.4 IU/kg/week or 0.06 mg/kg/day

    Drug: Genotonorm

Interventions

  • 0.7 IU/kg/week or 0.03 mg/kg/day, daily subcutaneous injection

  • 1.4 IU/kg/week or 0.06 mg/kg/day, daily subcutaneous injection

  • 1.4 IU/kg/week or 0.06 mg/kg/day, daily subcutaneous injection Intermittent treatment (6 months with treatment and 6 months without)

07

What researchers measure

Primary outcomes

  1. Change From Baseline in Annual Growth Rate Measured at 2 Years Following Treatment With Genotonorm

    Annual growth rate was expressed as height velocity (centimeter \[cm\]/year). This was derived by substracting annual growth rate at Baseline from 2-year value. (Annual growth rate was calculated each year and rescaled to 1 year if the interval between x and x-1 was not 365 days, as long as a subject remains in the study): ANGRYx = (Height Yx - Height Y{x-1}) / {(Date of Yx - Date of Y{x-1}) /365.25}

    Time frame: Baseline, 2 years

Secondary outcomes

  1. Annual Growth Rate Standard Deviation Score (SDS)

    Calculated using Sempe reference means and standard deviations for growth rate according to age and sex. Standardization was performed for chronological age.

    Time frame: Baseline, 1 to 6 years

  2. Change From Baseline in Annual Growth Rate SDS

    Calculated corresponding to the gender and chronological age by substracting annual growth rate SDS at Baseline from annual growth rate SDS at each year.

    Time frame: Baseline, 1 to 3 years

  3. Height (cm)

    Performed by use of a wallmounted device (eg, Harpenden Stadiometer). Each subject was measured 3 times and the mean of these measurements was recorded as the present height. Final Height: Children are defined as reaching their final height when annual Growth Rate is less than 2 cm in the previous year and bone age is equal to or greater than 17 years in boys and equal to or greater than 15 years in girls.

    Time frame: Baseline, 1 to 6 years, final height

  4. Change From Baseline in Height (cm)

    Calculated by substracting height at Baseline from height at each year. Final Height: Children are defined as reaching their final height when annual Growth Rate is less than 2 cm in the previous year and bone age is equal to or greater than 17 years in boys and equal to or greater than 15 years in girls.

    Time frame: Baseline, 1 to 6 years, final height

  5. Height (SDS)

    Calculated using Sempe reference means and standard deviations for height. Final Height: Children are defined as reaching their final height when annual Growth Rate is less than 2 cm in the previous year and bone age is equal to or greater than 17 years in boys and equal to or greater than 15 years in girls.

    Time frame: Baseline, 1 to 6 years, final height

  6. Change From Baseline in Height (SDS)

    Calculated by substracting height SDS at Baseline from height SDS at each year. Final Height: Children are defined as reaching their final height when annual Growth Rate is less than 2 cm in the previous year and bone age is equal to or greater than 17 years in boys and equal to or greater than 15 years in girls.

    Time frame: Baseline, 1 to 6 years, final height

  7. Body Mass Index (BMI)

    BMI was calculated by weight divided by height squared.

    Time frame: Baseline, 1 to 6 years

  8. Weight

    Time frame: Baseline, 1 to 6 years

  9. Change From Baseline in Bone Age

    Bone age was determined by the Greulich-Pyle method. Calculated by substracting bone age at Baseline from bone age at each year

    Time frame: Baseline, 1 to 3 years

  10. Change From Baseline in Bone Age/Change From Baseline in Chronological Age Ratio

    Bone age was determined by the Greulich-Pyle method. Chronological Age (years) was calculated as: (Date minus Date of Birth) divided by 365.25. Chronological Age used was the age at the date that the corresponding Bone Age X-ray was performed. Ratio was calculated by change from Baseline in bone age divided by change from Baseline in chronological age.

    Time frame: 1 to 3 years

  11. Chronological Age at Onset of Puberty

    Chronological age (years) at first study visit with onset of puberty = (Date of study visit minus Date of Birth) divided by 365.25.

    Time frame: Onset of puberty

  12. Number of Subjects Reaching Puberty

    The defined criteria for reaching puberty were: boy=if right or left testes volume ≥4 ml; girl=if breast development ≥2. Tanner Adolescent Pubertal Staging Questionnaire documents the stage of development of secondary sexual characteristics rated in 5 stages: stage 1 (no development) to 5 (adult-like development in quantity and size). Onset of puberty was defined as the visit where the data recorded first met the above criteria for starting puberty.

    Time frame: Baseline, 1 to 6 years

08

Results

Posted Aug 31, 2010

Participant flow

Participant flow — Overall Study
MilestoneGenotonorm 0.7 (Continuous Treatment)Genotonorm 1.4 (Continuous Treatment)Genotonorm 1.4 (Intermittent Treatment)
Started687169
Received treatment687068
Completed648
Not completed626761
Withdrew: Ongoing at cutoff date110
Withdrew: Adverse event210
Withdrew: Lost to follow-up349
Withdrew: Other252129
Withdrew: Withdrawal by subject313922
Withdrew: Randomized but not treated011

Outcome measures

PrimaryChange From Baseline in Annual Growth Rate Measured at 2 Years Following Treatment With Genotonorm

Annual growth rate was expressed as height velocity (centimeter \[cm\]/year). This was derived by substracting annual growth rate at Baseline from 2-year value. (Annual growth rate was calculated each year and rescaled to 1 year if the interval between x and x-1 was not 365 days, as long as a subject remains in the study): ANGRYx = (Height Yx - Height Y{x-1}) / {(Date of Yx - Date of Y{x-1}) /365.25}

Time frame:
Baseline, 2 years
Reported as:
Mean · cm/year
Change From Baseline in Annual Growth Rate Measured at 2 Years Following Treatment With Genotonorm
cm/yearGenotonorm 0.7 (Continuous Treatment)Genotonorm 1.4 (Continuous Treatment)Genotonorm 1.4 (Intermittent Treatment)
Change From Baseline in Annual Growth Rate Measured at 2 Years Following Treatment With Genotonorm3.07 ± 2.213.97 ± 1.722.84 ± 1.71
Statistical analysis
  • Genotonorm 0.7 (Continuous Treatment) vs Genotonorm 1.4 (Continuous Treatment) · Wilcoxon (Mann-Whitney) · p = 0.02922 (P-values for the 3 treatment comparisons should be interpreted in line with the Bonferroni stepwise (Holm) testing procedure, to maintain the Type 1 error at p=0.05.)
  • Genotonorm 0.7 (Continuous Treatment) vs Genotonorm 1.4 (Intermittent Treatment) · Wilcoxon (Mann-Whitney) · p = 0.74299 (P-values for the 3 treatment comparisons should be interpreted in line with the Bonferroni stepwise (Holm) testing procedure, to maintain the Type 1 error at p=0.05.)
  • Genotonorm 1.4 (Continuous Treatment) vs Genotonorm 1.4 (Intermittent Treatment) · Wilcoxon (Mann-Whitney) · p = 0.00467 (P-values for the 3 treatment comparisons should be interpreted in line with the Bonferroni stepwise (Holm) testing procedure, to maintain the Type 1 error at p=0.05.)
SecondaryAnnual Growth Rate Standard Deviation Score (SDS)

Calculated using Sempe reference means and standard deviations for growth rate according to age and sex. Standardization was performed for chronological age.

Time frame:
Baseline, 1 to 6 years
Reported as:
Mean · SDS
Annual Growth Rate Standard Deviation Score (SDS)
SDSGenotonorm 0.7 (Continuous Treatment)Genotonorm 1.4 (Continuous Treatment)Genotonorm 1.4 (Intermittent Treatment)
Baseline (n=50, 42, 43)-2.72 ± 1.83-2.58 ± 1.39-2.75 ± 1.73
1 year (n=57, 55, 59)2.14 ± 1.523.97 ± 2.261.71 ± 1.51
2 years (n=53, 49, 56)0.77 ± 1.572.00 ± 1.730.67 ± 1.22
3 years (n=39, 34, 41)0.36 ± 1.141.35 ± 1.780.31 ± 1.12
4 years (n=21, 18, 27)0.13 ± 1.550.61 ± 1.200.34 ± 1.20
5 years (n=12, 10, 20)0.18 ± 1.240.09 ± 0.88-0.02 ± 1.46
6 years (n=11, 7, 19)0.90 ± 1.920.59 ± 1.610.05 ± 1.20
SecondaryChange From Baseline in Annual Growth Rate SDS

Calculated corresponding to the gender and chronological age by substracting annual growth rate SDS at Baseline from annual growth rate SDS at each year.

Time frame:
Baseline, 1 to 3 years
Reported as:
Mean · SDS
Change From Baseline in Annual Growth Rate SDS
SDSGenotonorm 0.7 (Continuous Treatment)Genotonorm 1.4 (Continuous Treatment)Genotonorm 1.4 (Intermittent Treatment)
1 year (n=49, 42, 42)4.81 ± 2.276.56 ± 2.554.37 ± 2.16
2 years (n=47, 37, 40)3.51 ± 2.504.53 ± 1.893.37 ± 2.33
3 years (n=34, 25, 32)3.31 ± 2.063.80 ± 2.203.17 ± 1.86
Statistical analysis
  • Genotonorm 0.7 (Continuous Treatment) vs Genotonorm 1.4 (Continuous Treatment) · Wilcoxon (Mann-Whitney) · p = 0.00125 (P-values for the 3 treatment comparisons should be interpreted in line with the Bonferroni stepwise (Holm) testing procedure, to maintain the Type 1 error at p=0.05.)
  • Genotonorm 0.7 (Continuous Treatment) vs Genotonorm 1.4 (Intermittent Treatment) · Wilcoxon (Mann-Whitney) · p = 0.25995 (P-values for the 3 treatment comparisons should be interpreted in line with the Bonferroni stepwise (Holm) testing procedure, to maintain the Type 1 error at p=0.05.)
  • Genotonorm 1.4 (Continuous Treatment) vs Genotonorm 1.4 (Intermittent Treatment) · Wilcoxon (Mann-Whitney) · p = 0.00008 (P-values for the 3 treatment comparisons should be interpreted in line with the Bonferroni stepwise (Holm) testing procedure, to maintain the Type 1 error at p=0.05.)
  • Genotonorm 0.7 (Continuous Treatment) vs Genotonorm 1.4 (Continuous Treatment) · Wilcoxon (Mann-Whitney) · p = 0.03273 (P-values for the 3 treatment comparisons should be interpreted in line with the Bonferroni stepwise (Holm) testing procedure, to maintain the Type 1 error at p=0.05.)
  • Genotonorm 0.7 (Continuous Treatment) vs Genotonorm 1.4 (Intermittent Treatment) · Wilcoxon (Mann-Whitney) · p = 0.68581 (P-values for the 3 treatment comparisons should be interpreted in line with the Bonferroni stepwise (Holm) testing procedure, to maintain the Type 1 error at p=0.05.)
  • Genotonorm 1.4 (Continuous Treatment) vs Genotonorm 1.4 (Intermittent Treatment) · Wilcoxon (Mann-Whitney) · p = 0.00530 (P-values for the 3 treatment comparisons should be interpreted in line with the Bonferroni stepwise (Holm) testing procedure, to maintain the Type 1 error at p=0.05.)
  • Genotonorm 0.7 (Continuous Treatment) vs Genotonorm 1.4 (Continuous Treatment) · Wilcoxon (Mann-Whitney) · p = 0.57556 (P-values for the 3 treatment comparisons should be interpreted in line with the Bonferroni stepwise (Holm) testing procedure, to maintain the Type 1 error at p=0.05.)
  • Genotonorm 0.7 (Continuous Treatment) vs Genotonorm 1.4 (Intermittent Treatment) · Wilcoxon (Mann-Whitney) · p = 0.63956 (P-values for the 3 treatment comparisons should be interpreted in line with the Bonferroni stepwise (Holm) testing procedure, to maintain the Type 1 error at p=0.05.)
  • Genotonorm 1.4 (Continuous Treatment) vs Genotonorm 1.4 (Intermittent Treatment) · Wilcoxon (Mann-Whitney) · p = 0.16421 (P-values for the 3 treatment comparisons should be interpreted in line with the Bonferroni stepwise (Holm) testing procedure, to maintain the Type 1 error at p=0.05.)
SecondaryHeight (cm)

Performed by use of a wallmounted device (eg, Harpenden Stadiometer). Each subject was measured 3 times and the mean of these measurements was recorded as the present height. Final Height: Children are defined as reaching their final height when annual Growth Rate is less than 2 cm in the previous year and bone age is equal to or greater than 17 years in boys and equal to or greater than 15 years in girls.

Time frame:
Baseline, 1 to 6 years, final height
Reported as:
Mean · cm
Height (cm)
cmGenotonorm 0.7 (Continuous Treatment)Genotonorm 1.4 (Continuous Treatment)Genotonorm 1.4 (Intermittent Treatment)
Baseline (n=58, 56, 60)105.22 ± 15.04107.06 ± 12.29106.44 ± 12.04
1 year (n=57, 55, 59)113.38 ± 15.09116.31 ± 12.24113.71 ± 12.01
2 years (n=53, 49, 56)119.67 ± 15.18124.11 ± 13.02120.64 ± 12.34
3 years (n=39, 34, 41)123.92 ± 15.08131.75 ± 13.76125.39 ± 12.52
4 years (n=21, 18, 27)124.67 ± 13.14132.30 ± 13.23127.59 ± 11.51
5 years (n=12, 10, 21)126.73 ± 10.01131.01 ± 9.26129.98 ± 9.93
6 years (n=11, 7, 20)133.29 ± 10.46138.84 ± 8.69135.45 ± 10.10
Final height (n=17, 12, 22)146.86 ± 11.26151.98 ± 6.52149.13 ± 9.07
SecondaryChange From Baseline in Height (cm)

Calculated by substracting height at Baseline from height at each year. Final Height: Children are defined as reaching their final height when annual Growth Rate is less than 2 cm in the previous year and bone age is equal to or greater than 17 years in boys and equal to or greater than 15 years in girls.

Time frame:
Baseline, 1 to 6 years, final height
Reported as:
Mean · cm
Change From Baseline in Height (cm)
cmGenotonorm 0.7 (Continuous Treatment)Genotonorm 1.4 (Continuous Treatment)Genotonorm 1.4 (Intermittent Treatment)
1 year (n=57, 55, 59)8.21 ± 1.389.21 ± 1.457.33 ± 1.32
2 years (n=53, 49, 56)14.77 ± 2.4517.01 ± 2.2113.92 ± 2.03
3 years (n=39, 34, 41)20.62 ± 3.0024.49 ± 3.0420.14 ± 2.78
4 years (n=21, 18, 27)26.36 ± 4.3730.77 ± 3.4325.83 ± 3.26
5 years (n=12, 10, 21)32.23 ± 5.9235.70 ± 4.2732.16 ± 3.81
6 years (n=11, 7, 20)38.20 ± 6.6644.03 ± 3.0938.01 ± 4.82
Final height (n=17, 12, 22)45.39 ± 13.0845.30 ± 13.7240.93 ± 9.22
SecondaryHeight (SDS)

Calculated using Sempe reference means and standard deviations for height. Final Height: Children are defined as reaching their final height when annual Growth Rate is less than 2 cm in the previous year and bone age is equal to or greater than 17 years in boys and equal to or greater than 15 years in girls.

Time frame:
Baseline, 1 to 6 years, final height
Reported as:
Mean · SDS
Height (SDS)
SDSGenotonorm 0.7 (Continuous Treatment)Genotonorm 1.4 (Continuous Treatment)Genotonorm 1.4 (Intermittent Treatment)
Baseline (n=58, 56, 60)-3.16 ± 0.52-3.07 ± 0.46-3.21 ± 0.65
1 year (n=57, 55, 59)-2.49 ± 0.54-2.17 ± 0.50-2.68 ± 0.69
2 years (n=53, 49, 56)-2.21 ± 0.66-1.68 ± 0.52-2.38 ± 0.75
3 years (n=39, 34, 41)-2.17 ± 0.70-1.38 ± 0.57-2.24 ± 0.90
4 years (n=21, 18, 27)-2.16 ± 1.03-1.16 ± 0.73-2.09 ± 0.96
5 years (n=12, 10, 21)-1.95 ± 1.26-1.15 ± 0.83-1.96 ± 1.10
6 years (n=11, 7, 19)-1.80 ± 1.28-0.67 ± 0.66-1.93 ± 1.18
Final height (n=14, 9, 18)-2.06 ± 0.76-1.97 ± 0.95-2.29 ± 1.35
SecondaryChange From Baseline in Height (SDS)

Calculated by substracting height SDS at Baseline from height SDS at each year. Final Height: Children are defined as reaching their final height when annual Growth Rate is less than 2 cm in the previous year and bone age is equal to or greater than 17 years in boys and equal to or greater than 15 years in girls.

Time frame:
Baseline, 1 to 6 years, final height
Reported as:
Mean · SDS
Change From Baseline in Height (SDS)
SDSGenotonorm 0.7 (Continuous Treatment)Genotonorm 1.4 (Continuous Treatment)Genotonorm 1.4 (Intermittent Treatment)
1 year (n=57, 55, 59)0.67 ± 0.280.88 ± 0.300.53 ± 0.28
2 years (n=53, 49, 56)0.94 ± 0.451.40 ± 0.430.84 ± 0.37
3 years (n=39, 34, 41)1.06 ± 0.541.70 ± 0.540.99 ± 0.51
4 years (n=21, 18, 27)1.20 ± 0.811.98 ± 0.691.21 ± 0.54
5 years (n=12, 10, 21)1.37 ± 1.122.03 ± 0.871.46 ± 0.69
6 years (n=11, 7, 19)1.54 ± 1.122.60 ± 0.661.54 ± 0.86
Final height (n=14, 9, 18)1.00 ± 0.530.97 ± 0.950.86 ± 1.16
Statistical analysis
  • Genotonorm 0.7 (Continuous Treatment) vs Genotonorm 1.4 (Continuous Treatment) · Wilcoxon (Mann-Whitney) · p = 0.0001 (P-values for the 3 treatment comparisons should be interpreted in line with the Bonferroni stepwise (Holm) testing procedure, to maintain the Type 1 error at p=0.05.)
  • Genotonorm 0.7 (Continuous Treatment) vs Genotonorm 1.4 (Intermittent Treatment) · Wilcoxon (Mann-Whitney) · p = 0.58324 (P-values for the 3 treatment comparisons should be interpreted in line with the Bonferroni stepwise (Holm) testing procedure, to maintain the Type 1 error at p=0.05.)
  • Genotonorm 1.4 (Continuous Treatment) vs Genotonorm 1.4 (Intermittent Treatment) · Wilcoxon (Mann-Whitney) · p = <0.0001 (P-values for the 3 treatment comparisons should be interpreted in line with the Bonferroni stepwise (Holm) testing procedure, to maintain the Type 1 error at p=0.05.)
SecondaryBody Mass Index (BMI)

BMI was calculated by weight divided by height squared.

Time frame:
Baseline, 1 to 6 years
Reported as:
Mean · kg/m^2
Body Mass Index (BMI)
kg/m^2Genotonorm 0.7 (Continuous Treatment)Genotonorm 1.4 (Continuous Treatment)Genotonorm 1.4 (Intermittent Treatment)
Baseline (n=58, 56, 60)14.74 ± 1.4815.14 ± 1.7614.59 ± 1.51
1 year (n=56, 55, 59)14.82 ± 1.5215.44 ± 1.9414.87 ± 1.76
2 years (n=53, 49, 56)15.33 ± 1.7815.92 ± 2.1515.29 ± 2.00
3 years (n=39, 34, 41)15.59 ± 2.0216.65 ± 2.9215.58 ± 2.11
4 years (n=21, 18, 27)15.32 ± 1.5617.03 ± 3.7015.80 ± 2.37
5 years (n=12, 10, 21)15.80 ± 1.5716.25 ± 1.7016.69 ± 3.92
6 years (n=11, 7, 20)16.21 ± 1.4616.34 ± 1.8017.28 ± 4.21
SecondaryWeight
Time frame:
Baseline, 1 to 6 years
Reported as:
Mean · kg
Weight
kgGenotonorm 0.7 (Continuous Treatment)Genotonorm 1.4 (Continuous Treatment)Genotonorm 1.4 (Intermittent Treatment)
Baseline (n=58, 56, 60)16.77 ± 5.4317.70 ± 5.1216.79 ± 4.35
1 year (n=56, 55, 59)19.71 ± 6.2821.29 ± 6.0419.56 ± 5.17
2 years (n=53, 49, 56)22.66 ± 7.6225.08 ± 7.4322.64 ± 6.05
3 years (n=39, 34, 41)24.77 ± 8.8029.61 ± 9.6224.98 ± 7.05
4 years (n=21, 18, 27)24.30 ± 7.0130.56 ± 10.4226.28 ± 7.94
5 years (n=12, 10, 21)25.74 ± 6.2228.07 ± 5.2228.52 ± 8.96
6 years (n=11, 7, 21)29.13 ± 6.4231.94 ± 7.2832.30 ± 10.32
SecondaryChange From Baseline in Bone Age

Bone age was determined by the Greulich-Pyle method. Calculated by substracting bone age at Baseline from bone age at each year

Time frame:
Baseline, 1 to 3 years
Reported as:
Mean · Years
Change From Baseline in Bone Age
YearsGenotonorm 0.7 (Continuous Treatment)Genotonorm 1.4 (Continuous Treatment)Genotonorm 1.4 (Intermittent Treatment)
1 year (n=53, 60, 56)1.17 ± 0.511.27 ± 0.721.25 ± 0.54
2 years (n=52, 51, 49)2.40 ± 0.902.50 ± 1.082.58 ± 0.97
3 years (n=41, 39, 35)3.53 ± 1.224.06 ± 1.053.67 ± 0.97
SecondaryChange From Baseline in Bone Age/Change From Baseline in Chronological Age Ratio

Bone age was determined by the Greulich-Pyle method. Chronological Age (years) was calculated as: (Date minus Date of Birth) divided by 365.25. Chronological Age used was the age at the date that the corresponding Bone Age X-ray was performed. Ratio was calculated by change from Baseline in bone age divided by change from Baseline in chronological age.

Time frame:
1 to 3 years
Reported as:
Mean · ratio
Change From Baseline in Bone Age/Change From Baseline in Chronological Age Ratio
ratioGenotonorm 0.7 (Continuous Treatment)Genotonorm 1.4 (Continuous Treatment)Genotonorm 1.4 (Intermittent Treatment)
1 year (n=53, 60, 56)0.96 ± 0.411.07 ± 0.621.06 ± 0.45
2 years (n=51, 51, 49)1.06 ± 0.411.14 ± 0.501.18 ± 0.44
3 years (n=35, 37, 35)1.09 ± 0.391.26 ± 0.321.14 ± 0.29
SecondaryChronological Age at Onset of Puberty

Chronological age (years) at first study visit with onset of puberty = (Date of study visit minus Date of Birth) divided by 365.25.

Time frame:
Onset of puberty
Reported as:
Mean · Years
Chronological Age at Onset of Puberty
YearsGenotonorm 0.7 (Continuous Treatment)Genotonorm 1.4 (Continuous Treatment)Genotonorm 1.4 (Intermittent Treatment)
Chronological Age at Onset of Puberty11.88 ± 2.2211.12 ± 1.7411.58 ± 1.42
Statistical analysis
  • Genotonorm 0.7 (Continuous Treatment) vs Genotonorm 1.4 (Continuous Treatment) · ANCOVA · p = 0.0681 (There is no adjustment for multiplicity of treatment comparisons.) · Mean difference (final values): 0.67 · 95% CI -0.05 to 1.39The Analysis of Covariance took into account the patient covariates age and gender.
  • Genotonorm 0.7 (Continuous Treatment) vs Genotonorm 1.4 (Intermittent Treatment) · ANCOVA · p = 0.8971 (There is no adjustment for multiplicity of treatment comparisons.) · Mean difference (final values): 0.05 · 95% CI -0.65 to 0.74The Analysis of Covariance took into account the patient covariates age and gender.
  • Genotonorm 1.4 (Continuous Treatment) vs Genotonorm 1.4 (Intermittent Treatment) · ANCOVA · p = 0.0583 (There is no adjustment for multiplicity of treatment comparisons.) · Mean difference (final values): -0.63 · 95% CI -1.27 to 0.02The Analysis of Covariance took into account the patient covariates age and gender.
SecondaryNumber of Subjects Reaching Puberty

The defined criteria for reaching puberty were: boy=if right or left testes volume ≥4 ml; girl=if breast development ≥2. Tanner Adolescent Pubertal Staging Questionnaire documents the stage of development of secondary sexual characteristics rated in 5 stages: stage 1 (no development) to 5 (adult-like development in quantity and size). Onset of puberty was defined as the visit where the data recorded first met the above criteria for starting puberty.

Time frame:
Baseline, 1 to 6 years
Reported as:
Number · participants
Number of Subjects Reaching Puberty
participantsGenotonorm 0.7 (Continuous Treatment)Genotonorm 1.4 (Continuous Treatment)Genotonorm 1.4 (Intermittent Treatment)
Baseline (Female, Not Started)253139
Baseline (Male, Not Started)433929
1 year (Female, Not Started)242737
1 year (Female, Started)132
1 year (Male, Not Started)363527
1 year (Male, Started)431
2 years (Female, Not Started)202031
2 years (Female, Started)376
2 years (Male, Not Started)312820
2 years (Male, Started)976
3 years (Female, Not Started)161016
3 years (Female, Started)3911
3 years (Male, Not Started)19159
3 years (Male, Started)674
4 years (Female, Not Started)10710
4 years (Female, Started)257
4 years (Male, Not Started)1057
4 years (Male, Started)123
5 years (Female, Not Started)545
5 years (Female, Started)2310
5 years (Male, Not Started)664
5 years (Male, Started)211
6 years (Female, Not Started)333
6 years (Female, Started)3212
6 years (Male, Not Started)541
6 years (Male, Started)314

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Genotonorm 0.7 (Continuous Treatment)—0/68 (0%)40/68 (58.8%)
Genotonorm 1.4 (Continuous Treatment)—4/70 (5.7%)42/70 (60%)
Genotonorm 1.4 (Intermittent Treatment)—3/68 (4.4%)35/68 (51.5%)
Most frequent serious events
Most frequent serious events
EventGenotonorm 0.7 (Continuous Treatment)Genotonorm 1.4 (Continuous Treatment)Genotonorm 1.4 (Intermittent Treatment)
TonsillectomySurgical and medical procedures0/684/703/68
Most frequent other events
Showing 10 of 21
Most frequent other events
EventGenotonorm 0.7 (Continuous Treatment)Genotonorm 1.4 (Continuous Treatment)Genotonorm 1.4 (Intermittent Treatment)
Upper respiratory tract infectionInfections and infestations19/6819/7012/68
BronchitisInfections and infestations13/689/7017/68
NasopharyngitisInfections and infestations16/6816/7011/68
Ear infectionInfections and infestations15/6815/709/68
GastroenteritisInfections and infestations4/688/7011/68
InfluenzaInfections and infestations6/689/707/68
VaricellaInfections and infestations8/686/701/68
PharyngitisInfections and infestations2/686/707/68
RhinitisInfections and infestations4/682/706/68
DiarrhoeaGastrointestinal disorders5/680/704/68

Baseline characteristics

Age, Customized
Age, Customized(Participants)Genotonorm 0.7 (Continuous Treatment)Genotonorm 1.4 (Continuous Treatment)Genotonorm 1.4 (Intermittent Treatment)Total
< 4 years158629
4 - 8 years29322990
8 - 12 years23303386
>= 12 years1001
Sex: Female, Male
Sex: Female, Male(Participants)Genotonorm 0.7 (Continuous Treatment)Genotonorm 1.4 (Continuous Treatment)Genotonorm 1.4 (Intermittent Treatment)Total
Female25313995
Male433929111
09

Study locations

30 sites
  • Pfizer Investigational Site
    Amiens, 80030, France
  • Pfizer Investigational Site
    Angers cedex, 49933, France
  • Pfizer Investigational Site
    Besancon Cedex, 25030, France
  • Pfizer Investigational Site
    Bordeaux Cedex, 33076, France
  • Pfizer Investigational Site
    Bordeaux, 33000, France
  • Pfizer Investigational Site
    Boulogne, 92100, France
  • Pfizer Investigational Site
    Brest, 29200, France
  • Pfizer Investigational Site
    Bron Cedex, 69677, France
  • Pfizer Investigational Site
    Clermont Ferrand, 63000, France
  • Pfizer Investigational Site
    Dijon, 21034, France
  • Pfizer Investigational Site
    Grenoble, 38043, France
  • Pfizer Investigational Site
    Hyères, 83407, France
  • Pfizer Investigational Site
    Lille, 59000, France
  • Pfizer Investigational Site
    Lille, 59037, France
  • Pfizer Investigational Site
    Marseille cedex 5, 13385, France
  • Pfizer Investigational Site
    Montpellier, 34059, France
  • Pfizer Investigational Site
    Nantes Cedex 1, 44093, France
  • Pfizer Investigational Site
    Nice, 06202, France
  • Pfizer Investigational Site
    Paris, 75019, France
  • Pfizer Investigational Site
    Paris, 75571, France
  • Pfizer Investigational Site
    Paris, 75674, France
  • Pfizer Investigational Site
    Reims, 51092, France
  • Pfizer Investigational Site
    Rennes, 35033, France
  • Pfizer Investigational Site
    Rouen, 76000, France
  • Pfizer Investigational Site
    Saint Priest en Jarez, 42277, France
  • Pfizer Investigational Site
    Strasbourg Cedex 2, 67098, France
  • Pfizer Investigational Site
    Tarbes, France
  • Pfizer Investigational Site
    Toulouse Cedex, 31026, France
  • Pfizer Investigational Site
    Tours, 37044, France
  • Pfizer Investigational Site
    Vandoeuvre Les Nancy Cedex, 54511, France
10

References and documents

11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 1993, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2010, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2010
First posted
Feb 23, 2010
Start
Jul 1993
Primary completionActual
May 2009
CompletionActual
May 2009
Results first posted
Aug 31, 2010
Last update
Nov 18, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01073605
Lead sponsor
Pfizer
First posted
Feb 23, 2010
Start date
Jul 1993
Primary completion
May 2009
Completion
May 2009
Results posted
Aug 31, 2010
Last update
Nov 18, 2010

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion